240 related articles for article (PubMed ID: 18074354)
1. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.
Almeida GM; Duarte TL; Farmer PB; Steward WP; Jones GD
Int J Cancer; 2008 Apr; 122(8):1810-9. PubMed ID: 18074354
[TBL] [Abstract][Full Text] [Related]
2. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
3. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
[TBL] [Abstract][Full Text] [Related]
4. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
5. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
6. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.
Arienti C; Zoli W; Pignatta S; Carloni S; Paganelli G; Ulivi P; Romeo A; Menghi E; Sarnelli A; Medri L; Polico R; Silvestrini R; Tesei A
J Cell Physiol; 2014 Oct; 229(10):1548-56. PubMed ID: 24591063
[TBL] [Abstract][Full Text] [Related]
8. Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line.
Gu Y; Fan S; Xiong Y; Peng B; Zheng G; Yu Y; Ouyang Y; He Z
FEBS Lett; 2011 Mar; 585(6):881-7. PubMed ID: 21334329
[TBL] [Abstract][Full Text] [Related]
9. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.
Wei L; Wang XW; Sun JJ; Lv LY; Xie L; Song XR
Asian Pac J Cancer Prev; 2015; 16(3):875-80. PubMed ID: 25735376
[TBL] [Abstract][Full Text] [Related]
12. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
[TBL] [Abstract][Full Text] [Related]
13. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
14. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
16. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
[TBL] [Abstract][Full Text] [Related]
17. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Weaver DA; Crawford EL; Warner KA; Elkhairi F; Khuder SA; Willey JC
Mol Cancer; 2005 May; 4(1):18. PubMed ID: 15882455
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
19. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]